Navigation Links
DAVISCO Foods International, Inc. and MEGGLE Group Announce a Joint Venture for the Production of Pharmaceutical Lactose.
Date:11/16/2009

EDEN PRAIRIE, Minn., Nov. 16 /PRNewswire/ -- Announced on November 06, 2009 by Mr. Mark Davis, the President and CEO of DAVISCO Foods International Inc., and the Board of MEGGLE Group of Wasserburg, Germany, represented by Drs Sil H. van der Ploeg, CEO, and Mr. Christian Sedlatschek, CFO, the companies are entering a long-term partnership for the production of pharmaceutical lactose in the United States.

DAVISCO Foods is an international cheese and food ingredient company, founded in 1943, headquartered in Le Sueur, MN., a privately-held, family-owned business. DAVISCO is a company committed to technical advancement, customer service, and the production of superior quality products.

The holding group MEGGLE AG, whose headquarters are in Wasserburg, Germany was founded in 1887 and bundles the activities of the different companies within the milk and whey-processing business group. This structure embodies flexibility and decisiveness on the one hand and the traditional character of the dairy with its long history of milk-processing on the other. The Business Group Excipients & Technology is considered the leading producer of pharmaceutical lactose and excels in particular in offering High - Tech, innovative excipients to the pharmaceutical industry worldwide.

DAVISCO will expand their existing lactose production at the Le Sueur facility to accommodate additional production lines for the production of pharmaceutical lactose utilizing state-of-the-art processing technology.

MEGGLE will provide the technical marketing, sales and distribution for the pharmaceutical lactose products.

"DAVISCO Foods Intl. Inc. is excited and honored to engage in a joint venture with the MEGGLE Company to produce pharmaceutical lactose products. We have had a close and rewarding relationship for years with MEGGLE and have respected and admired their many achievements. The joint venture will produce the same high quality products and provide the same service that MEGGLE has historically produced and provided." Mr. Mark Davis, President DAVISCO Food International Inc.

"MEGGLE highly appreciates the partnership with DAVISCO. This is an important step in our strategy to expand our capacities and at the same time to offer our customers worldwide the security of a second production site." Drs Sil H. van der Ploeg, CEO of MEGGLE

www.DAVISCOFoods.com

www.MEGGLE.com

SOURCE DAVISCO Foods International, Inc.


'/>"/>
SOURCE DAVISCO Foods International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Soyfoods Do Not Impact Sperm Count
2. New Database from ANSI, AAMI, ASTM International, and DIN Provides Centralized Source of Information for Medical Device Professionals
3. Natural Alternatives International, Inc. Announces Filing of Patent Infringement Lawsuit
4. Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results
5. Chindex International, Inc. to Report Second Quarter Fiscal 2010 Financial Results
6. Medizone International, Inc. (MZEI.PK): Trials of the AsepticSure Hospital Sterilization System Have Begun
7. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
8. Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors
9. WellTek/MedX Group Completes Major Reorganization
10. Hill-Rom and Encompass Group Form Joint Venture
11. GSI Group Inc. Announces NASDAQ Delisting and Reports Progress on Revenue Recognition Review and Preliminary Third Quarter 2009 Bookings and Cash Balance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Henry Schein, Inc. (Nasdaq: ... care products and services to office-based dental, animal health and ... equity investment in Marrodent, one of Poland,s ... $32 million. This transaction was announced on August 30, 2016. ... Poland since 2014, and Marrodent marks ...
(Date:12/8/2016)... Dec 8, 2016 Research and Markets has announced ... report to their offering. ... , The report provides separate comprehensive ... , and Rest of World. Annual estimates and ... historic analysis is provided for these markets. Market data and analytics are ...
(Date:12/7/2016)... Dec. 7, 2016 "Lantus (Insulin Glargine) Biosimilar Clinical Trial & ... biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar version ... Japan , Kenya , Czech ... , China , Slovakia , ... 2 diabetes mellitus. The patent on Lantus expired in 2014. Lantus ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a ... and commercial clients in the northern Alabama and Georgia regions, is embarking on ... 1977, Nobis Works has built a network of support and education facilities to ...
(Date:12/7/2016)... , ... December 07, 2016 , ... DrugDev ... announcement that it is one of the early adopters completing EU-U.S. Privacy Shield Certification ... designed to provide companies on both sides of the Atlantic with a mechanism to ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... celebrating the passage of the most comprehensive mental health systems reform legislation in ... support of the President, and the commitment of our elected officials to improving ...
(Date:12/7/2016)... York, NY (PRWEB) , ... December 07, 2016 ... ... amounts of the drug in their bodies, a researcher at the Icahn School ... journal Pediatric Research. , The study found that when young children are exposed ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... of Smart Device Remote Control through a new partnership with Splashtop Inc. This ... strengthens its mobile solutions to help businesses maximize their uptime and productivity. , ...
Breaking Medicine News(10 mins):